Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZU2G1)

• Drug Name: LMP-1/LMP-2 CTLs Drug Info
• Synonyms: Ad5f35LMPd1-2; LMP-1/LMP-2 CTLs, Baylor College of Medicine/NCI; LMP-1/LMP-2 specific cytotoxic T-lymphocytes (gene therapy,nasopharyngeal cancer/lymphoma), Baylor College of Medicine/NCI

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMZU2G1

Molecule-Related Drug Atlas

Drug(s) Targeting Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad5f35-LMPd1-2-transduced autologous dendritic cells	DMQW612	Nasopharyngeal carcinoma	2B6B	Investigative	[3]

Drug(s) Targeting Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMP1-CAR-T cells	DMYGNDI	Nasopharyngeal carcinoma	2B6B	Phase 1/2	[4]
Ad5f35-LMPd1-2-transduced autologous dendritic cells	DMQW612	Nasopharyngeal carcinoma	2B6B	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)	TT0BI4Q	LMP1_EBVG	Modulator	[2]
Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)	TTBK351	LMP2_EBVB9	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00062868) LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma. U.S. National Institutes of Health.
• [2] In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
• [3] CA patent application no. 876139, Nanotherapeutics for drug targeting.
• [4] ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application